Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis [PDF]
Frontiers in Pharmacology, 2023 Background and aims: Hypoglycemic agents are the primary therapeutic approach for the treatment of diabetes and have been postulated to impact pancreatic cancer (PC) incidence in diabetic patients.
Zimo Zhao, Xinyi He, Yan Sun
doaj +5 more sources
Hypoglycemic Agents and Anesthetic Techniques to Ameliorate Stress Hyperglycemia in Critically Ill Patients: A Systematic Review [PDF]
Journal of Research in Pharmacy Practice, 2023 The concurrent utilization of hypoglycemic agents and anesthetic techniques has been demonstrated to mitigate stress hyperglycemia in critically ill patients without diabetes, thereby contributing to enhanced patient outcomes.
Fatemeh Rahimpour +4 more
doaj +4 more sources
Pharmacogenetics of hypoglycemic agents [PDF]
Сахарный диабет, 2015 Despite the increase in the number of hypoglycemic agents, 35%–40% of patients with diabetes are unable to achieve adequate glycemic control. One of the reasons is the genetic heterogeneity of diabetes mellitus, requiring different treatment approaches ...
Irina Vladimirovna Kononenko +3 more
doaj +4 more sources
Risk of non-hypoglycemic agents for hypoglycemia-related hospitalization in patients with type 2 diabetes: a large-scale medical receipt database analysis [PDF]
BMJ Open Diabetes Research & Care, 2023 Introduction Hypoglycemia is listed as an adverse effect in the package inserts of not only hypoglycemic agents but also many other drugs. We aimed to clarify real-world factors related to an increased risk of hypoglycemia-related hospitalization (HRH ...
Takeshi Horii, Mai Otsuka, Takeo Yasu
doaj +2 more sources
Re-starting or initiating guideline-recommended hypoglycemic agents for patients admitted with hyperglycemic crisis [PDF]
Frontiers in MedicineIntroductionHyperglycemic crises, such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), are life-threatening complications of diabetes. This study aimed to assess the impact of early initiation of non-insulin hypoglycemic agents
Abdulrahman I. Alshaya +18 more
doaj +2 more sources
Adulteration of hypoglycemic products: the silent threat [PDF]
Romanian Journal of Medical Practice, 2023 Background. The growing tendency toward the adulteration of hypoglycemic products in the market to increase the seller’s profits, the increased promotions of such products by unscrupulous promoters, and the higher rate of consumption by diabetic patients
Raniah I. Alnaser +2 more
doaj +3 more sources
Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition [PDF]
Acta Pharmaceutica Sinica B, 2023 Jincheng Wang
exaly +2 more sources
Cocos Nucifera Endocarp Extract Exhibits Anti-diabetic and Antilipidemic Activities in Diabetic Rat Model [PDF]
International Journal of Scientific Research in Dental and Medical Sciences, 2022 Background and aim: The fruits of Cocos nucifera have long been used in traditional medicine as anti-inflammatory, antimicrobial, antiparasitic, anticancer, and cardiotonic.
Farjana Akter +5 more
doaj +1 more source
Blood glucose, antidiabetic drugs, and risk of stroke [PDF]
Precision and Future Medicine, 2021 Diabetes mellitus is a well-established risk factor for stroke. Among people without baseline diabetes or cardiovascular disease, a low fasting glucose level of < 70 mg/dL is associated with an increased risk of stroke.
Meng Lee, Bruce Ovbiagele
doaj +1 more source
INTERACTIONS OF CELECOXIB WITH DIFFERENT ANTIDIABETIC DRUGS IN DIABETIC RATS [PDF]
Bulletin of Pharmaceutical Sciences. Assiut University, 2016 The selective cyclooxygenase-2 inhibitor, celecoxib, can be prescribed to type 2 diabetic patients receiving oral hypoglycemic agents. This study was conducted to assess whether celecoxib affect the hypoglycemic activity of oral hypoglycemic agents in ...
Manar Nader, Shehta Said, Manar Helal
doaj +1 more source